Back |
home / stock / bvxv / bvxv message board
Subject | By | Source | When |
---|---|---|---|
BiondVax Announces Closing of $12.1 Million Follow-on Underwritten Offering | pennystock_es | investorshub | 02/02/2021 9:44:53 PM |
BiondVax Announces Pricing of $12.1 Million Follow-on Underwritten | midastouch017 | investorshub | 01/29/2021 1:07:49 PM |
BiondVax Announces Launch of Proposed Underwritten Follow-on Offering | midastouch017 | investorshub | 01/29/2021 5:30:10 AM |
BiondVax Announces Third Quarter 2020 Financial Results & | midastouch017 | investorshub | 01/29/2021 5:29:11 AM |
Added $BVXV friday. MM's are manipulating as usual | lukin4winners | investorshub | 01/23/2021 3:33:43 PM |
News, Short Squeeze, Breakout and More Instantly...
BiondVax Pharmaceuticals Ltd. Company Name:
BVXV Stock Symbol:
NASDAQ Market:
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...